TNFR2 signaling in musculoskeletal diseases: Implications for rheumatoid arthritis and osteoarthritis
Journal of Leukocyte Biology · 2025
DOI: 10.1093/jleuko/qiaf178 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Leukocyte Biology, 2025. Verfasst von Emily Qian und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics and Rehabilitation, Yale University School of Medicine, 789 Howard Avenue, New Haven, CT 06519, United States. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Signal Transduction, Osteoarthritis, Receptors, Tumor Necrosis Factor, Type II. Die Arbeit nennt 148 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIAMS NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Arthritis imposes a substantial global burden and remains without curative therapy. Among the most prevalent forms, rheumatoid arthritis and osteoarthritis differ in etiology but converge on pathogenic tumor necrosis factor α (TNFα) signaling. A key regulatory node is TNFR2, which promotes immunomodulation and tissue repair in contrast to the proinflammatory signaling of TNFR1. Progranulin (PGRN), a high-affinity TNFR2 ligand, protects joints by orchestrating macrophage plasticity and chondrocyte metabolism. Central to this pathway is the adaptor protein 14-3-3ε, an essential intracellular component of the PGRN/TNFR2 complex. In macrophages, 14-3-3ε directs PI3K/Akt-mTOR signaling to restrain NF-κB and promote C/EBPβ-driven M2 polarization, while in chondrocytes it enables ERK/Elk-1 activation to sustain anabolism. Across inflammatory and degenerative models, genetic loss of PGRN, TNFR2, or 14-3-3ε abolishes protection, whereas recombinant PGRN or the engineered PGRN-derived molecule Atsttrin attenuates arthritis, preserves cartilage, and enhances bone repair. Incorporation of Atsttrin into biomaterials such as hydrogels and 3D-printed scaffolds further augments efficacy and durability in preclinical studies. This review briefly summarizes current evidence positioning the PGRN/TNFR2/14-3-3ε complex as a shared mechanism in rheumatoid arthritis and osteoarthritis pathogenesis and repair, and highlights translational opportunities—from TNFR2 agonism to Atsttrin-based therapeutics—for disease modification in arthritis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedics and Rehabilitation, Yale University School of Medicine, 789 Howard Avenue, New Haven, CT 06519, United States.
ORCID-Profile: Chuan-Ju Liu
Förderung
- NIH HHS
- NIAMS NIH HHS
- NINDS NIH HHS
- NIDDK NIH HHS
- Yale Department of Orthopaedics and Rehabilitation
- National Institutes of Health
Zitieren
APA
Qian, E., MacLeod, R. S., & Liu, C. J. (2025). TNFR2 signaling in musculoskeletal diseases: Implications for rheumatoid arthritis and osteoarthritis. Journal of Leukocyte Biology. https://doi.org/10.1093/jleuko/qiaf178
Vancouver
Qian E, MacLeod RS, Liu CJ. TNFR2 signaling in musculoskeletal diseases: Implications for rheumatoid arthritis and osteoarthritis. Journal of Leukocyte Biology. 2025. doi:10.1093/jleuko/qiaf178
BibTeX
@article{Qian2025,
author = {Qian, Emily and MacLeod, Ryan S and Liu, Chuan-Ju},
title = {TNFR2 signaling in musculoskeletal diseases: Implications for rheumatoid arthritis and osteoarthritis},
journal = {Journal of Leukocyte Biology},
year = {2025},
doi = {10.1093/jleuko/qiaf178}
}
EUVIMED